Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
6
Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
6
Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
6
Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
6
Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
6
Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
